<SEC-DOCUMENT>0001648257-25-000085.txt : 20251217
<SEC-HEADER>0001648257-25-000085.hdr.sgml : 20251217
<ACCEPTANCE-DATETIME>20251217060449
ACCESSION NUMBER:		0001648257-25-000085
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251217
FILED AS OF DATE:		20251217
DATE AS OF CHANGE:		20251217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUTCHMED (China) Ltd
		CENTRAL INDEX KEY:			0001648257
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37710
		FILM NUMBER:		251577185

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		48TH FLOOR, CHEUNG KONG CENTER
		STREET 2:		2 QUEEN'S ROAD CENTRAL
		CITY:			HONG KONG
		PROVINCE COUNTRY:   	K3
		BUSINESS PHONE:		852-2121-3888

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		48TH FLOOR, CHEUNG KONG CENTER
		STREET 2:		2 QUEEN'S ROAD CENTRAL
		CITY:			HONG KONG
		PROVINCE COUNTRY:   	K3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Hutchison China MediTech Ltd
		DATE OF NAME CHANGE:	20150716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>hcm-20251217x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 12/17/2025 09:36:27 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:1pt;padding-top:1pt;text-align:right;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 1.5pt 0pt 0pt;"><font style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:18pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">FORM&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:16pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:18pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Month of </b><b style="font-weight:bold;">December</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number: 001-37710</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">HUTCHMED (CHINA) LIMITED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Translation of registrant&#8217;s name into English)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">48th Floor, Cheung Kong Center, 2 Queen&#8217;s Road Central, Hong Kong</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Form&#160;20-F&#160;&#160;<font style="font-family:'Times New Roman';">&#8999;</font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;<font style="font-family:'Times New Roman';">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HUTCHMED (CHINA) LIMITED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT&#160;INDEX</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:87.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style=""><td style="vertical-align:top;width:11.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exhibit 99.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 36pt 0pt 0pt;"><font style="font-weight:normal;">Press release </font><font style="font-weight:normal;">relating</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-weight:normal;letter-spacing:-0.1pt;">the </font><font style="font-weight:normal;letter-spacing:-0.1pt;">initiation</font><font style="font-weight:normal;letter-spacing:-0.1pt;"> of </font><font style="font-weight:normal;letter-spacing:-0.1pt;">global clinical development of ATTC </font><font style="font-weight:normal;letter-spacing:-0.1pt;">c</font><font style="font-weight:normal;letter-spacing:-0.1pt;">andidate HMPL-A251 in patients with solid tumors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:10pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">HUTCHMED (CHINA) LIMITED</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">/s/ Johnny Cheng</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:41.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Johnny Cheng</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Date: December 17, 2025</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:10pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hcm-20251217xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 12/17/2025 09:36:27 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:32.3%;">&#9;</font><font style="display:inline-block;width:11.76%;">&#9;</font><font style="display:inline-block;width:38.55%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">Exhibit 99.1</b></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><img src="hcm-20251217xex99d1001.gif" alt="Graphic" style="display:inline-block;height:44.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160.15pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">                                              </font><font style="font-size:12pt;white-space:pre-wrap;">                                                                                                          </font><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk181768051"></a><b style="font-weight:bold;">Press Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 43.2pt 0pt 43.2pt;"><b style="font-size:14pt;font-weight:bold;">HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 7.2pt 8pt 7.2pt;"><i style="font-style:italic;">&#8212; First-in-human trial of candidate from the next-generation ATTC platform&#160;&#8212;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 7.2pt 12pt 25.2pt;"><i style="font-style:italic;">&#8212; Simultaneous China and global clinical development strategy to expedite development process &#8212;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Hong Kong, Shanghai &amp; Florham Park, NJ &#8212;&#160;&#160;&#160;Wednesday, December 17, 2025: </b>HUTCHMED (China) Limited (&#8220;<u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED</u>&#8221;) (Nasdaq/AIM:&#8203;HCM; <a name="_Hlk162538399"></a>HKEX:&#8203;13) today announces the initiation of its global Phase I clinical development program for HMPL-A251, a first-in-class PI3K/PIKK-HER2 Antibody-Targeted Therapy Conjugate (&#8220;ATTC&#8221;) comprising a highly selective and potent PI3K/PIKK inhibitor payload conjugated to a humanized anti-HER2 IgG1 antibody via a cleavable linker. Study sites are in the US and China. The first patient received the first dose on December 16, 2025, in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">This first-in-human Phase I/IIa, open-label, multicenter clinical study evaluates HMPL-A251 monotherapy in adult patients with unresectable, advanced or metastatic HER2-expressing solid tumors. The study is divided into two parts, a Phase I dose escalation part and a Phase IIa dose expansion and optimization part. The primary outcome measures are to evaluate the safety and tolerability of HMPL-A251 and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (&#8220;RDE&#8221;) in the Phase I part, and to further evaluate safety and preliminary efficacy at RDEs and to determine the recommended dose for Phase II (RP2D) or Phase III (RP3D) in the Phase IIa part. Secondary outcome measures include preliminary antitumor activity, pharmacokinetic profile, and the immunogenicity of HMPL-A251. Additional details may be found at clinicaltrials.gov, using identifier&#160;<u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">NCT07228247</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">HMPL-A251 is the first clinical-stage candidate derived from HUTCHMED&#8217;s next-generation ATTC platform. The first family of programs are based on a highly potent and selective PI3K/PIKK inhibitor payload. By conjugating this highly novel payload to an anti-HER2 antibody, the molecule is designed to deliver targeted pathway inhibition directly into HER2-expressing tumor cells, thereby potentially overcoming the systemic toxicity and narrow therapeutic index historically associated with PI3K/PIKK inhibitors. This approach aims to achieve deeper and more durable target inhibition while improving the overall tolerability profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Preclinical data for HMPL-A251 were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This body of evidence supports the translational potential of the ATTC platform, the ongoing global clinical evaluation of HMPL-A251, and the broad potential of HUTCHMED&#8217;s PI3K/PIKK inhibitor linker-payload to underpin a family of future ATTC drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:10pt 0pt 6pt 0pt;"><b style="font-weight:bold;">About the ATTC Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">HUTCHMED&#8217;s ATTC platform represents a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action. Unlike traditional cytotoxin-based Antibody Drug Conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in efficacy and safety. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Built on over 20 years of targeted therapy expertise, the platform enables development of drug candidates for diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve the accessibility to tumors and reduce off-tumor toxicity. This overcomes challenges of traditional small-molecule inhibitors, ensures safer long-term use, and supports combinations with chemotherapy and immunotherapy, unlocking potential for early-line treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">About the PAM Pathway and HMPL-A251 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The PI3K/AKT/mTOR (&#8220;PAM&#8221;) pathway is a critical intracellular network involved in cell growth, survival, and division. Alterations in the PAM pathway are frequently associated with poor prognosis and resistance to treatment across various cancers. However, existing PAM-targeted drugs face significant challenges, including on-target toxicities that restrict dosing, feedback loops that enable pathway reactivation, and insufficient tumor-specific delivery. HUTCHMED has designed a highly novel PI3K/PIKK inhibitor linker-payload to overcome these challenges with broad potential to lead to a family of antibody conjugate drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">HMPL-A251 is a first-in-class ATTC comprising of this highly selective and potent PI3K/PIKK inhibitor payload conjugated to a humanized anti-HER2 IgG1 antibody via a cleavable linker, designed to address challenges by enhancing targeted delivery directly to tumor cells, maximizing therapeutic benefit while minimizing systemic exposure. In preclinical studies, the HMPL-A251 payload exhibited high selectivity, potency, and robust anti-tumor activity. HMPL-A251 exhibited superior anti-tumor efficacy and tolerability compared to co-administration of the naked antibody and payload. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:10pt 0pt 6pt 0pt;"><b style="font-weight:bold;">About HUTCHMED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">HUTCHMED (Nasdaq/AIM:&#8203;HCM; HKEX:&#8203;13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">www.hutch-med.com</u> or follow us on <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">LinkedIn</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;"><font style="font-style:italic;font-weight:bold;">Forward-Looking Statements </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;"><a name="_Hlk136438441"></a></font><i style="font-style:italic;">This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED&#8217;s current expectations regarding future events, including its expectations regarding the therapeutic potential of </i><i style="font-style:italic;">HMPL-A251 </i><i style="font-style:italic;">and</i><i style="font-style:italic;"> other drug candidates from the ATTC platform</i><i style="font-style:italic;"> and the further development of </i><i style="font-style:italic;">HMPL-A251 </i><i style="font-style:italic;">and</i><i style="font-style:italic;"> other drug candidates from the ATTC platform</i><i style="font-style:italic;"> in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support an new drug application submission of </i><i style="font-style:italic;">HMPL-A251 </i><i style="font-style:italic;">and</i><i style="font-style:italic;"> other drug candidates from the ATTC platform</i><i style="font-style:italic;"> in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the efficacy and safety profile of </i><i style="font-style:italic;">HMPL-A251 </i><i style="font-style:italic;">and</i><i style="font-style:italic;"> other drug candidates from the ATTC platform</i><i style="font-style:italic;">, HUTCHMED&#8217;s ability to fund, implement and complete its further clinical development and commercialization plans for </i><i style="font-style:italic;">HMPL-A251 </i><i style="font-style:italic;">and</i><i style="font-style:italic;"> other drug candidates from the ATTC platform</i><i style="font-style:italic;"> and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED&#8217;s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:10pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CONTACTS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.15pt 0pt 2.15pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Investor Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+852&#160;2121&#160;8200 / <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">ir@hutch-med.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Media Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FTI&#160;Consulting &#8211;</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;3727&#160;1030&#160;/ <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED@fticonsulting.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">   Ben Atwell / Tim Stamper</font></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">   +44&#160;7771&#160;913&#160;902&#160;(Mobile)&#160;/ +44&#160;7421&#160;898&#160;348 (Mobile)</font></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brunswick &#8211; Zhou Yi</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+852&#160;9783&#160;6894&#160;(Mobile)&#160;/ <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED@brunswickgroup.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Panmure Liberum</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Nominated Advisor and Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Atholl Tweedie&#160;/ Emma Earl&#160;/ Rupert Dearden</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;7886&#160;2500</p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cavendish</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Geoff Nash&#160;/ Nigel Birks</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;7220&#160;0500</p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Deutsche Numis</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Freddie Barnfield / Jeffrey Wong / Duncan Monteith</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44 20 7260 1000</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hcm-20251217xex99d1001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hcm-20251217xex99d1001.gif
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MH''GQH8Y=RX0 $H>O5XZ'! @($#KUP<PJ,G31#*! "OU%D0CP/#M"P1K0)!
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M^.2*"1%DT&%XQX.(:G&+CP*6B/$>7OB28#  K3(?45",9--J;_E0##510B(
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M \U5$&"0 QJPCEF& 2A@!0R%$$V0 SL@JE33$&'  QY@ <!J 1D@ CS 'V&
MJJ+J% D1!\@:-3Y $%V0!$LPK4I@C0OQ!DHPK4N0!,$Y$&:P!-FJK>(JKDPP
2$FX@K>.JK5B@!68 H!\1$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
